Synovis takes Veritas biomaterial to Canada:
This article was originally published in Clinica
Executive Summary
Synovis Surgical Innovations has gained approval in Canada to market its implantable remodellable biomaterial for use in three applications - pelvic floor reconstruction, pelvic organ prolapse repair and as a sling for the treatment of stress urinary incontinence. The Veritas collagen matrix product is currently being assessed in studies at five US centres. Clinical data from the studies, so far, indicate that the implant is efficacious in the approved applications, with no infections, rejections or erosion of the implanted tissue, said the St Paul, Minnesota firm, a division of Synovis Life Technologies. The Veritas implant is already cleared in the US for the same applications.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.